Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763798 | 0.85 | CA12 (0.51) | SLC9A1LMNAALDH1A1MAPK1 | |
| SCHEMBL6674304 | 0.85 | CISD1 (0.50) | SLC9A1LMNAALDH1A1MAPK1 | |
| SCHEMBL7764035 | 0.85 | SLC9A1 (0.45) | SLC9A1LMNAALDH1A1MAPK1 | |
| SCHEMBL6922321 | 0.85 | SLC9A1 (0.49) | SLC9A1LMNAALDH1A1MAPK1KDM4E | |
| SCHEMBL6901487 | 0.82 | SLC9A1 (0.43) | SLC9A1LMNAALDH1A1MAPK1 | |
| SCHEMBL6719348 | 0.82 | SLC9A1 (0.57) | SLC9A1 | |
| SCHEMBL8059191 | 0.81 | SLC9A1 (0.42) | SLC9A1LMNAALDH1A1MAPK1HSD17B10 | |
| SCHEMBL9018704 | 0.79 | SLC9A1 (0.41) | SLC9A1LMNAALDH1A1MAPK1 | |
| SCHEMBL13751701 | 0.79 | ALDH1A1 (0.49) | SLC9A1LMNAALDH1A1MAPK1HPGD | |
| SCHEMBL6749760 | 0.79 | SLC9A1 (0.54) | SLC9A1ALDH1A1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098866-B1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-02-11 | — | — | EP | claimed |
| US-6573404-B2 | Intermediates in industrial organic synthesis, e.g. in the preparation of fine chemicals, dyes and crop-protection compositions | MERCK PATENT GMBH (DE) | 2003-06-03 | — | — | US | claimed |
| US-20030069444-A1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | MERCK KGAA (DE) | 2003-04-10 | — | — | US | claimed |
| JP-2002521352-A | — | — | 2002-07-16 | — | — | JP | claimed |
| US-20020091286-A1 | Method for producing ortho-alkylated benzoic acid derivatives | MERCK GMBH (DE) | 2002-07-11 | — | — | US | claimed |
| EP-1098866-A1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | MERCK PATENT GmbH (DE) | 2001-05-16 | — | — | EP | claimed |
| WO-2000005187-A1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-02-03 | — | — | WO | claimed |
| US-20070299139-A1 | Lyophilisate Comprising N-Diaminomethylene-2-Methyl-4,5-Di(Methylsulfonyl)Benzamide | MERCK PATENT GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
| EP-1791528-A1 | LYOPHILISATE CONTAINING N-DIAMINOMETHYLENE-2-METHYL-4,5-DI-(METHYLSULFONYL)-BENZAMIDE | Merck Patent GmbH (DE) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006032386-A1 | LYOPHILISATE CONTAINING N-DIAMINOMETHYLENE-2-METHYL-4,5-DI-(METHYLSULFONYL)-BENZAMIDE | MERCK PATENT GMBH (DE) | 2006-03-30 | — | — | WO | disclosed |
| EP-1098866-B1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-02-11 | — | — | EP | disclosed |
| US-6673968-B1 | REACTING 4-CHLORO-2-METHYL-5-(METHYLSULFONYL)BENZOIC ACID WITH SODIUM METHANESULFINATE, THEN WITH GUANIDINE, SALT FORMATION; ANTIARRHYTHMIC; NHE-1 SELECTIVE NA+/H+ ANTIPORTER INHIBITOR | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2004-01-06 | — | — | US | disclosed |
| EP-1224166-B1 | METHOD OF PRODUCING N-(4,5-BIS-METHANESULFONYL-2-METHYL-BENZOYL)-GUANIDINE, THE HYDROCHLORIDE THEREOF | MERCK PATENT GMBH (DE) | 2003-09-17 | — | — | EP | disclosed |
| US-6515143-B2 | 2-bromo-5-chlorotoluene is reacted with a secondary or tertiary organolithium compound, and carbon dioxide to give 4-chloro-2-methylbenzoic acid | MERCK KGAA (DE) | 2003-02-04 | — | — | US | disclosed |
| EP-1224166-A1 | METHOD OF PRODUCING N-(4,5-BIS-METHANESULFONYL-2-METHYL-BENZOYL)-GUANIDINE, THE HYDROCHLORIDE THEREOF | MERCK PATENT GmbH (DE) | 2002-07-24 | — | — | EP | disclosed |
| US-20020091286-A1 | Method for producing ortho-alkylated benzoic acid derivatives | MERCK GMBH (DE) | 2002-07-11 | — | — | US | disclosed |
| US-6350904-B1 | CATALYTIC CARBOXYLATION OF HALOALKYLBENZENE | MERCK KGAA (DE) | 2002-02-26 | — | — | US | disclosed |
| EP-1098866-A1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | MERCK PATENT GmbH (DE) | 2001-05-16 | — | — | EP | disclosed |
| WO-2001030750-A1 | METHOD OF PRODUCING N-(4,5-BIS-METHANESULFONYL-2-METHYL-BENZOYL)-GUANIDINE, THE HYDROCHLORIDE THEREOF | MERCK PATENT GMBH (DE) | 2001-05-03 | — | — | WO | disclosed |
| WO-2000005187-A1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091286-A1 | Method for producing ortho-alkylated benzoic acid derivatives | AOC2, OXER1, GABBR2 | SLC9A1 2216/4885LMNA 3337/4885ALDH1A1 870/4885 |
| US-20030069444-A1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | AOC2, OXER1, GABBR2 | SLC9A1 2216/4885LMNA 3337/4885ALDH1A1 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.